Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ZBIO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
31 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 2
145 filers reported a long position in ZBIO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $241.3M | 9.5M | +4.7% |
| SR ONE CAPITAL MANAGEMENT, LP | $127.9M | 5M | Unchanged |
| NEA Management Company, LLC | $102.1M | 4M | Unchanged |
| Enavate Sciences GP, LLC | $99.5M | 3.9M | Unchanged |
| FEDERATED HERMES, INC. | $79.1M | 3.1M | -0.3% |
| BlackRock, Inc. | $68.2M | 2.7M | +31.8% |
| Capital International Investors | $63.5M | 2.5M | +2.8% |
| Polar Capital Holdings Plc | $61.2M | 2.4M | -5.3% |
| Royalty Pharma Sub-Manager, LLC | $60.6M | 2.4M | Unchanged |
| Fairmount Funds Management LLC | $59.9M | 2.4M | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.